Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease

Drug Safety

Volumn 25, Issue 1, 2002, Pages 57-71

  Bonay, Marcel ^a,b   Bancal, Catherine ^a   Crestani, Bruno ^a,b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; METHACHOLINE; PLACEBO; PREDNISOLONE; SALBUTAMOL; TERBUTALINE; TRIAMCINOLONE;

ADRENAL SUPPRESSION; ASTHMA; BONE DENSITY; BRONCHIECTASIS; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; DYSPHONIA; FEMUR; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HOARSENESS; HUMAN; INTRAOCULAR HYPERTENSION; LUMBAR SPINE; LUNG FUNCTION; META ANALYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SORE THROAT;

EID: 0036190092     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225010-00005     Document Type: Review

References (70)

1. Mortality by cause for eight regions of the world: Global Burden of Disease Study
2. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
3. Predictors of loss of lung function and mortality in obstructive lung diseases
4. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1
5. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma
6. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice
7. Analysis of inhaled coticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995
8. Chronic obstructive pulmonary disease
9. Cellular and structural bases of chronic obstructive pulmonary disease
10. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis
11. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma
12. Circulating cell adhesion molecules in bronchoalveoloar lavage and serum in COPD patients with chronic bronchitis
13. Granulocyte activation markers in induced sputum: Comparison between chronic obstructive pulmonary disease, asthma, and normal subjects
14. Airway eosinophilia in chronic bronchitis during exacerbations
15. Non-eosinophilic corticosteroid unresponsive asthma
16. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
17. Alveolar inflammation and its relation to emphysema in smokers
18. Altered cytokine regulation in the lungs of cigarette smokers
19. Longitudinal analysis of airway responsiveness and pulmonary function decline
20. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease
21. Airways responsiveness and development and remission of chronic respiratory symptoms in adults
22. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1: A longitudinal study in the elderly
23. The relationship of non specific airway responsiveness and atopy to the rate of decline of lung function. The Normative Aging Study
24. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: The Normative Aging Study
25. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease
26. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease
27. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema
28. The immunological component of cellular inflammatory infiltrate in bronchiectasis
29. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis
30. A. Inhaled corticosteroids in stable COPD patients. Do they have effects on cells and molecular mediators of airway inflammation?
31. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease
32. Corticosteroid reversibility in COPD is related to features of asthma
33. Sputum eosinophilia predicts benefit from prednisolone in smokers with chronic obstructive bronchitis
34. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema
35. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial
36. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease
37. Aerosolized beclomethasone in chronic bronchitis: Improved pulmonary function and diminished airway inflammation
38. Corticosteroid trials in non-asthmatic chronic airflow obstruction: A comparison of oral prednisolone and inhaled beclomethasone dipropionate
39. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction
40. Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5′-monophosphate in COPD
41. The effect of high dose inhaled beclomethasone dipropionate in patients with stable COPD
42. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease
43. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction
44. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction
45. Severe chronic airflow obstruction: Can corticosteroids slow down progression?
46. Moderately severe chronic airflow obstruction: Can corticosteroids slow down progression?
47. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: A 4-year prospective study
48. Effects of long term treatment with corticosteroids in COPD
49. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis
50. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
51. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
52. Long term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
53. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
54. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
55. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects
56. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
57. Corticosteroids in chronic obstructive pulmonary disease
58. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to moderate asthma
59. Acute adrenal insufficiency associated with high-dose inhaled steroids
60. Effects of inhaled glucocorticoids on bone density in premenopausal women
61. A meta-analysis of the effects of cigarette smoking on bone mineral density
62. Risk of osteoporosis in men with chronic bronchitis
63. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease
64. Prevalence and incidence of vertebral fractures in the elderly: Initial results from the Framingham study
65. Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy: A case-report with a review of the literature
66. Association of inhaled corticosteroid use with cataract extraction in elderly patients
67. Use of inhaled corticosteroids and the risk of cataracts
68. The risk of cataract among users of inhaled steroids
69. Easy bruising as a side-effect of inhaled corticosteroids
70. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease